Can a new PET imaging tracer distinguish different tau diseases?

What type of tau filaments are characteristically associated with Alzheimer's disease versus progressive supranuclear palsy (PSP)?

Alzheimer's disease is characterized by paired helical filaments of tau, whereas progressive supranuclear palsy (PSP) is characterized by straight tau filaments.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Why did the researchers use dynamic PET imaging with kinetic modelling instead of standardized uptake value ratios (SUVR) for 18F-AV-1451?

Kinetic modelling was chosen to account for individual variations in cerebral perfusion, which can otherwise decrease the reliability of SUVR.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

What specific clinical phenotype of progressive supranuclear palsy (PSP) was recruited for this study?

The study recruited patients meeting 'probable PSP' criteria who presented with the classical phenotype, often called Richardson's syndrome.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

How did the researchers verify biomarker evidence of Alzheimer's disease pathology in the Mild Cognitive Impairment (MCI) cohort?

All MCI participants were confirmed to have amyloid-beta pathology via a positive 11C-PiB PET scan.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Which brain region served as the reference tissue for 18F-AV-1451 PET analysis and why?

The superior grey matter of the cerebellum was used because it has little or no tau pathology in either progressive supranuclear palsy (PSP) or Alzheimer's disease.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

How did the authors correct their region of interest data for cerebrospinal fluid (CSF) partial volume effects?

They divided the data by the mean region of interest probability of grey plus white matter segments, which were smoothed to match PET resolution.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Which kinetic model was utilized to calculate the non-displaceable binding potential (BP_ND) of 18F-AV-1451?

A basis function implementation of the simplified reference tissue model (SRTM) was used.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

What threshold was used to define a 11C-PiB PET scan as positive for amyloid-beta pathology?

A scan was considered positive if the ratio of average SUVR values across cortical regions to cerebellar regions was greater than 1.5.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

What machine learning classifier was employed to differentiate Alzheimer's disease patients from PSP cases using PET data?

A Support Vector Machine (SVM) classifier utilizing a linear kernel and a K-means cross-validation scheme.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

What notable demographic difference was observed in patients with progressive supranuclear palsy (PSP) compared to other groups in this study?

PSP patients reported a significantly shorter duration of education compared to the other groups.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Where was 18F-AV-1451 binding highest in patients with Alzheimer's disease and biomarker-positive MCI compared to controls?

In cortical and subcortical areas, specifically frontal, parietal, lateral temporal, and occipital cortices, as well as the hippocampus.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

In which brain regions did PSP patients show increased 18F-AV-1451 binding relative to healthy controls?

In the putamen, pallidum, thalamus, midbrain, and the dentate nucleus of the cerebellum.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Did regional 18F-AV-1451 binding correlate with disease severity in either the Alzheimer's/MCI or PSP groups?

No, there were no significant correlations found between 18F-AV-1451 binding and cognitive scores (ACE-R) in Alzheimer's, or the PSP Rating Scale in PSP.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

With what accuracy was the SVM analysis able to separate Alzheimer's/MCI+ patients from PSP cases using selected regional 18F-AV-1451 data?

The SVM classifier separated the two clinical groups with 94.1% accuracy.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

What did post-mortem phosphor screen autoradiography demonstrate regarding 18F-AV-1451 binding in the Alzheimer's disease brain tissue sample?

The hippocampus showed the highest and most specific binding of the 18F-AV-1451 radiotracer.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

What was observed regarding 18F-AV-1451 binding in post-mortem PSP brain tissue sections?

PSP tissues exhibited sparse and non-specific 18F-AV-1451 binding across all examined regions, including the hippocampus, midbrain, basal ganglia, and frontal cortex.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

In which brain region were neuromelanin-containing cells exclusively observed in the post-mortem analysis?

Neuromelanin-containing cells were only observed in the midbrain across all post-mortem cases.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

How did the post-mortem findings challenge the theory that neuromelanin explains high 18F-AV-1451 binding in the basal ganglia?

No neuromelanin-containing cells were found in the basal ganglia of any case, despite high in vivo 18F-AV-1451 binding in that region.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Why is the cross-sectional nature of this study a limitation when evaluating 18F-AV-1451 as a clinical trial biomarker?

Cross-sectional data cannot determine longitudinal changes or show how the PET signal changes over time or in response to therapy.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Why was comparing Alzheimer's disease and PSP useful if they are already easily distinguished on clinical grounds?

It allowed researchers to test the ligand's in vivo binding against highly distinct spatial distributions of paired helical versus straight tau filaments.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Which tau isoforms are characteristically aggregated in Alzheimer's disease versus progressive supranuclear palsy (PSP)?

Alzheimer's disease features balanced 3R and 4R tau isoforms, whereas PSP pathology consists mainly of the 4R tau isoform.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

What step in the post-mortem autoradiographic protocol might have artificially reduced 18F-AV-1451 labeling in subcortical structures?

The ethanol washing steps and other histological procedures may have altered or diminished the radiotracer's specific binding.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

How did analyzing uncorrected PET data (without CSF partial volume correction) affect the study's overall results?

The uncorrected analyses yielded qualitatively similar results, confirming that the findings were robust and not artifactually created by CSF volume corrections.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

What did PET imaging reveal about 18F-AV-1451 binding in the basal ganglia of healthy controls?

Healthy controls exhibited high 18F-AV-1451 binding in the basal ganglia, suggesting substantial non-specific or off-target binding in this region.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

What is the primary clinical promise of quantitative in vivo tau PET biomarkers like 18F-AV-1451?

Measuring tau burden in living patients represents a major step forward for developing and tracking disease-modifying therapies targeting tau.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

How selective is 18F-AV-1451 for hyperphosphorylated tau relative to amyloid-beta plaques in post-mortem tissue?

Post-mortem studies indicate that 18F-AV-1451 co-localizes selectively with hyperphosphorylated tau over amyloid-beta plaques.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Which clinical presentation of Alzheimer's disease shows the highest 18F-AV-1451 binding in left posterior temporo-parietal areas?

The logopenic variant of Alzheimer's disease, which is linked to language and linguistic deficits.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Where do patients with the classical amnestic presentation of Alzheimer's disease show the highest 18F-AV-1451 uptake?

They show the highest uptake in the medial temporal lobe regions, particularly the hippocampus.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Why did the authors group clinical Alzheimer's disease and biomarker-positive MCI patients together for analysis?

Because clinical AD and prodromal MCI with positive amyloid markers represent a single continuous disease spectrum.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Which specific brain regions were selected as key features for the SVM classifier to differentiate AD and PSP?

The superior/inferior temporal, lateral occipital, and inferior parietal cortices, the hippocampus, basal ganglia, and midbrain.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

What was the classification accuracy of the SVM when separating progressive supranuclear palsy (PSP) patients from healthy controls?

The classification accuracy was 90.6%.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Which movement disorder does PSP-parkinsonism clinically resemble, posing a diagnostic challenge?

It clinically resembles Parkinson's disease, making early clinical differentiation difficult.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Besides Alzheimer's and PSP, what other neurological conditions exhibit pathological tau accumulation?

Fronto-temporal dementia, corticobasal degeneration, Parkinson's disease, Huntington's disease, and multiple sclerosis.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified

Which form of tau aggregates is proposed to drive primary cellular toxicity over mature tangles?

The toxicity is hypothesized to be driven by soluble tau oligomers rather than large, fibrillar tangles.

Source: 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy · DOI · quote verified